Pfizer Signs Academic Collaboration Pact With Peking University To Support Translational R&D Center In Shenzhen
SHANGHAI - After unveiling a plan to build a research and development center in Wuhan last week, Pfizer announced it inked an agreement with Peking University Dec. 1 to fund the university's research projects and to build a translational research and drug discovery center in PKU's Graduate School in Shenzhen, a Chinese city that borders the former British enclave of Hong Kong
More from Archive
More from Scrip
Recent moves in the industry include changes at the top at Novo Nordisk and Takeda, plus Nxera Pharma nabs chief commercial officer from AstraZeneca.
China’s imposed large retaliatory tariffs on US pharmaceuticals on 10 April, but some domestic firms with in-licensed, US-origin assets were already moving to localized manufacturing.
The end of semaglutide and tirzepatide shortages means large-scale compounding is declining, ICER noted. But compounded versions – and the demand for them – are likely here to stay.